{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-024002","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.019034+00:00","generated_at":"2026-06-15T04:18:25.360903+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AVROBIO Q1 net loss $25.0M, cash $72.3M; appoints interim CEO; GD3 trial on track","bullets":["Net loss of $25.0M for Q1 2023 vs $29.8M in Q1 2022; R&D expenses $17.3M, G&A $7.9M.","Cash and equivalents $72.3M as of March 31, 2023; expected runway into Q1 2024.","Plan to initiate registrational Phase 2/3 trial for Gaucher disease type 3 in H2 2023, subject to regulatory alignment.","Appointed CFO Erik Ostrowski as interim CEO, succeeding Geoff MacKay; board searching for permanent CEO.","Collaborator-sponsored Phase 1/2 trial for Hunter syndrome (MPS-II) initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-024002","json":"https://secwatch.observer/filing/0001140361-23-024002.json","markdown":"https://secwatch.observer/filing/0001140361-23-024002.md","text":"https://secwatch.observer/filing/0001140361-23-024002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123024002/0001140361-23-024002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123024002/brhc20052752_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:18:25.360903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9f0d79de35a074484e1c4224da96a68c407c74a4","claim":"Tectonic Therapeutic, Inc. reported the first quarter ended March 31, 2023 results: net income ($25.0 million).","evidence_excerpt":"AVROBIO reported a net loss of $25.0 million for the first quarter of 2023 as compared to a net loss of $29.8 million for the comparable period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681087/000114036123024002/0001140361-23-024002-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"($25.0 million)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}